Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference
March 03 2021 - 04:30PM
via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN),
today announced that company management will be participating in
the 2021 H.C. Wainwright Global Life Sciences Conference that is
scheduled to take place March 9-10, 2021. A recorded
presentation by Bill Little, Neovasc’s Chief Operating Officer,
will be available on the Conference website starting at 7:00 am EST
on March 9. Company management will also be scheduling
one-on-one meetings with investors; meetings may be requested
through H.C. Wainwright.
A link to the recorded presentation will also be available in
the investor relations section of the Neovasc website
at https://www.neovasc.com/investors/.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. The Company is a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies, and minimally invasive devices for the
treatment of refractory angina. Its products include the Neovasc
Reducer™, for the treatment of refractory angina, which is not
currently commercially available in the United States (2 U.S.
patients have been treated under Compassionate Use) and has been
commercially available in Europe since 2015, and Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel
and Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and applicable Canadian securities
laws that may not be based on historical fact. When used
herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to the
expansion of its product range and the growing cardiovascular
marketplace. Forward-looking statements are based on estimates and
assumptions made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments, as well as other factors that the Company
believes are appropriate in the circumstances. Many factors
could cause the Company's actual results, performance or
achievements to differ materially from those expressed or implied
by the forward-looking statements, including those described in the
"Risk Factors" section of the Company's Annual Report on Form 20-F
and in the Management's Discussion and Analysis for the three and
nine months ended September 30, 2020 (copies of which may be
obtained at www.sedar.com or www.sec.gov).
These factors should be considered carefully, and readers should
not place undue reliance on the Company's forward-looking
statements. The Company has no intention and undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Mar 2023 to Mar 2024